1887

Abstract

Dengue virus (DENV) is a mosquito-borne virus that causes severe health problems. An effective tetravalent dengue vaccine candidate that can provide life-long protection simultaneously against all four DENV serotypes is highly anticipated. A better understanding of the antibody response to DENV envelope protein domain III (EDIII) may offer insights into vaccine development. Here, we identified 25 DENV cross-reactive mAbs from immunization with -expressed EDIII of a single or all four serotype(s) using a prime–boost protocol, and through pepscan analysis found that 60 % of them (15/25) specifically recognized the same highly conserved linear epitope aa 309–320 of EDIII. All 15 complex-reactive mAbs exhibited significant cross-reactivity with recombinant EDIII from all DENV serotypes and also with C6/36 cells infected with DENV-1, -2, -3 and -4. However, neutralization assays indicated that the majority of these 15 mAbs were either moderately or weakly neutralizing. Through further epitope mapping by yeast surface display, two residues in the AB loop, Q316 and H317, were discovered to be critical. Three-dimensional modelling analysis suggests that this epitope is surface exposed on EDIII but less accessible on the surface of the E protein dimer and trimer, especially on the surface of the mature virion. It is concluded that EDIII as an immunogen may elicit cross-reactive mAbs toward an epitope that is not exposed on the virion surface, therefore contributing inefficiently to the mAbs neutralization potency. Therefore, the prime–boost strategy of EDIII from a single serotype or four serotypes mainly elicited a poorly neutralizing, cross-reactive antibody response to the conserved AB loop of EDIII.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.055178-0
2013-10-01
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/10/2191.html?itemId=/content/journal/jgv/10.1099/vir.0.055178-0&mimeType=html&fmt=ahah

References

  1. Cai J. P., Qian F., Wang J. Y., Zhao Y., Xu X. J., Jin W. R., Che X. Y.. ( 2010;). [Characterization and secreted expression of dengue virus type I-IV envelope glycoprotein domain III in Pichia pastoris]. . Zhonghua Yu Fang Yi Xue Za Zhi 44:, 721–725 (in Chinese).[PubMed]
    [Google Scholar]
  2. Che X. Y., Qiu L. W., Liao Z. Y., Wang Y. D., Wen K., Pan Y. X., Hao W., Mei Y. B., Cheng V. C., Yuen K. Y.. ( 2005;). Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. . J Infect Dis 191:, 2033–2037. [CrossRef][PubMed]
    [Google Scholar]
  3. Chen Y., Pan Y., Guo Y., Qiu L., Ding X., Che X.. ( 2010;). Comprehensive mapping of immunodominant and conserved serotype- and group-specific B-cell epitopes of nonstructural protein 1 from dengue virus type 1. . Virology 398:, 290–298. [CrossRef][PubMed]
    [Google Scholar]
  4. Chiang C. Y., Liu S. J., Tsai J. P., Li Y. S., Chen M. Y., Liu H. H., Chong P., Leng C. H., Chen H. W.. ( 2011;). A novel single-dose dengue subunit vaccine induces memory immune responses. . PLoS ONE 6:, e23319. [CrossRef][PubMed]
    [Google Scholar]
  5. Cockburn J. J., Navarro Sanchez M. E., Fretes N., Urvoas A., Staropoli I., Kikuti C. M., Coffey L. L., Arenzana Seisdedos F., Bedouelle H., Rey F. A.. ( 2012;). Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. . Structure 20:, 303–314. [CrossRef][PubMed]
    [Google Scholar]
  6. Ding X., Hu D., Chen Y., Di B., Jin J., Pan Y., Qiu L., Wang Y., Wen K.. & other authors ( 2011;). Full serotype- and group-specific NS1 capture enzyme-linked immunosorbent assay for rapid differential diagnosis of dengue virus infection. . Clin Vaccine Immunol 18:, 430–434. [CrossRef][PubMed]
    [Google Scholar]
  7. Falconar A. K.. ( 1999;). Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. . Arch Virol 144:, 2313–2330. [CrossRef][PubMed]
    [Google Scholar]
  8. Falconar A. K.. ( 2008;). Use of synthetic peptides to represent surface-exposed epitopes defined by neutralizing dengue complex- and flavivirus group-reactive monoclonal antibodies on the native dengue type-2 virus envelope glycoprotein. . J Gen Virol 89:, 1616–1621. [CrossRef][PubMed]
    [Google Scholar]
  9. Gromowski G. D., Barrett A. D.. ( 2007;). Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. . Virology 366:, 349–360. [CrossRef][PubMed]
    [Google Scholar]
  10. Gromowski G. D., Barrett N. D., Barrett A. D.. ( 2008;). Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. . J Virol 82:, 8828–8837. [CrossRef][PubMed]
    [Google Scholar]
  11. Halstead S. B.. ( 2007;). Dengue. . Lancet 370:, 1644–1652. [CrossRef][PubMed]
    [Google Scholar]
  12. Huisman W., Martina B. E., Rimmelzwaan G. F., Gruters R. A., Osterhaus A. D.. ( 2009;). Vaccine-induced enhancement of viral infections. . Vaccine 27:, 505–512. [CrossRef][PubMed]
    [Google Scholar]
  13. Kuhn R. J., Zhang W., Rossmann M. G., Pletnev S. V., Corver J., Lenches E., Jones C. T., Mukhopadhyay S., Chipman P. R., Strauss E. G.. ( 2002;). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. . Cell 108:, 717–725. [CrossRef][PubMed]
    [Google Scholar]
  14. Li J., Hu D. M., Ding X. X., Chen Y., Pan Y. X., Qiu L. W., Che X. Y.. ( 2011;). Enzyme-linked immunosorbent assay-format tissue culture infectious dose-50 test for titrating dengue virus. . PLoS ONE 6:, e22553. [CrossRef][PubMed]
    [Google Scholar]
  15. Lisova O., Hardy F., Petit V., Bedouelle H.. ( 2007;). Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. . J Gen Virol 88:, 2387–2397. [CrossRef][PubMed]
    [Google Scholar]
  16. Liu L., Wen K., Li J., Hu D., Huang Y., Qiu L., Cai J., Che X.. ( 2012;). Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein. . Clin Vaccine Immunol 19:, 73–78. [CrossRef][PubMed]
    [Google Scholar]
  17. Lok S. M., Kostyuchenko V., Nybakken G. E., Holdaway H. A., Battisti A. J., Sukupolvi-Petty S., Sedlak D., Fremont D. H., Chipman P. R.. & other authors ( 2008;). Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. . Nat Struct Mol Biol 15:, 312–317. [CrossRef][PubMed]
    [Google Scholar]
  18. Matsui K., Gromowski G. D., Li L., Schuh A. J., Lee J. C., Barrett A. D.. ( 2009;). Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. . Virology 384:, 16–20. [CrossRef][PubMed]
    [Google Scholar]
  19. Matsui K., Gromowski G. D., Li L., Barrett A. D.. ( 2010;). Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. . J Gen Virol 91:, 2249–2253. [CrossRef][PubMed]
    [Google Scholar]
  20. Midgley C. M., Flanagan A., Tran H. B., Dejnirattisai W., Chawansuntati K., Jumnainsong A., Wongwiwat W., Duangchinda T., Mongkolsapaya J.. & other authors ( 2012;). Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. . J Immunol 188:, 4971–4979. [CrossRef][PubMed]
    [Google Scholar]
  21. Modis Y., Ogata S., Clements D., Harrison S. C.. ( 2003;). A ligand-binding pocket in the dengue virus envelope glycoprotein. . Proc Natl Acad Sci U S A 100:, 6986–6991. [CrossRef][PubMed]
    [Google Scholar]
  22. Monath T. P.. ( 2007;). Dengue and yellow fever – challenges for the development and use of vaccines. . N Engl J Med 357:, 2222–2225. [CrossRef][PubMed]
    [Google Scholar]
  23. Murphy B. R., Whitehead S. S.. ( 2011;). Immune response to dengue virus and prospects for a vaccine. . Annu Rev Immunol 29:, 587–619. [CrossRef][PubMed]
    [Google Scholar]
  24. Pierson T. C., Diamond M. S.. ( 2008;). Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. . Expert Rev Mol Med 10:, e12. [CrossRef][PubMed]
    [Google Scholar]
  25. Pitcher T. J., Gromowski G. D., Beasley D. W., Barrett A. D.. ( 2012;). Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. . Virology 422:, 386–392. [CrossRef][PubMed]
    [Google Scholar]
  26. Rajamanonmani R., Nkenfou C., Clancy P., Yau Y. H., Shochat S. G., Sukupolvi-Petty S., Schul W., Diamond M. S., Vasudevan S. G., Lescar J.. ( 2009;). On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. . J Gen Virol 90:, 799–809. [CrossRef][PubMed]
    [Google Scholar]
  27. Roehrig J. T., Bolin R. A., Kelly R. G.. ( 1998;). Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. . Virology 246:, 317–328. [CrossRef][PubMed]
    [Google Scholar]
  28. Sabin A. B.. ( 1952;). Research on dengue during World War II. . Am J Trop Med Hyg 1:, 30–50.[PubMed]
    [Google Scholar]
  29. Scott T. W., Morrison A. C.. ( 2010;). Vector dynamics and transmission of dengue virus: implications for dengue surveillance and prevention strategies: vector dynamics and dengue prevention. . Curr Top Microbiol Immunol 338:, 115–128. [CrossRef][PubMed]
    [Google Scholar]
  30. Sukupolvi-Petty S., Austin S. K., Purtha W. E., Oliphant T., Nybakken G. E., Schlesinger J. J., Roehrig J. T., Gromowski G. D., Barrett A. D.. & other authors ( 2007;). Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. . J Virol 81:, 12816–12826. [CrossRef][PubMed]
    [Google Scholar]
  31. Sukupolvi-Petty S., Austin S. K., Engle M., Brien J. D., Dowd K. A., Williams K. L., Johnson S., Rico-Hesse R., Harris E.. & other authors ( 2010;). Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. . J Virol 84:, 9227–9239. [CrossRef][PubMed]
    [Google Scholar]
  32. Thomas S. J., Endy T. P.. ( 2011;). Vaccines for the prevention of dengue: development update. . Hum Vaccin 7:, 674–684. [CrossRef][PubMed]
    [Google Scholar]
  33. Thullier P., Demangel C., Bedouelle H., Mégret F., Jouan A., Deubel V., Mazié J. C., Lafaye P.. ( 2001;). Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. . J Gen Virol 82:, 1885–1892.[PubMed]
    [Google Scholar]
  34. Valdés I., Hermida L., Martín J., Menéndez T., Gil L., Lazo L., Castro J., Niebla O., López C.. & other authors ( 2009;). Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. . Vaccine 27:, 995–1001. [CrossRef][PubMed]
    [Google Scholar]
  35. Valdés I., Gil L., Romero Y., Castro J., Puente P., Lazo L., Marcos E., Guzmán M. G., Guillén G., Hermida L.. ( 2011;). The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. . Clin Vaccine Immunol 18:, 455–459. [CrossRef][PubMed]
    [Google Scholar]
  36. Volk D. E., Lee Y. C., Li X., Thiviyanathan V., Gromowski G. D., Li L., Lamb A. R., Beasley D. W., Barrett A. D., Gorenstein D. G.. ( 2007;). Solution structure of the envelope protein domain III of dengue-4 virus. . Virology 364:, 147–154. [CrossRef][PubMed]
    [Google Scholar]
  37. Wahala W. M., Kraus A. A., Haymore L. B., Accavitti-Loper M. A., de Silva A. M.. ( 2009;). Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. . Virology 392:, 103–113. [CrossRef][PubMed]
    [Google Scholar]
  38. Wahala W. M., Huang C., Butrapet S., White L. J., de Silva A. M.. ( 2012;). Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. . J Virol 86:, 4019–4023. [CrossRef][PubMed]
    [Google Scholar]
  39. Whitehead S. S., Blaney J. E., Durbin A. P., Murphy B. R.. ( 2007;). Prospects for a dengue virus vaccine. . Nat Rev Microbiol 5:, 518–528. [CrossRef][PubMed]
    [Google Scholar]
  40. Williams K. L., Wahala W. M., Orozco S., de Silva A. M., Harris E.. ( 2012;). Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. . Virology 429:, 12–20. [CrossRef][PubMed]
    [Google Scholar]
  41. Xu H., Di B., Pan Y. X., Qiu L. W., Wang Y. D., Hao W., He L. J., Yuen K. Y., Che X. Y.. ( 2006;). Serotype 1-specific monoclonal antibody-based antigen capture immunoassay for detection of circulating nonstructural protein NS1: implications for early diagnosis and serotyping of dengue virus infections. . J Clin Microbiol 44:, 2872–2878. [CrossRef][PubMed]
    [Google Scholar]
  42. Zhang Z. S., Yan Y. S., Weng Y. W., Huang H. L., Li S. Q., He S., Zhang J. M.. ( 2007;). High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. . J Virol Methods 143:, 125–131. [CrossRef][PubMed]
    [Google Scholar]
  43. Zlatkovic J., Stiasny K., Heinz F. X.. ( 2011;). Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. . J Virol 85:, 1994–2003. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.055178-0
Loading
/content/journal/jgv/10.1099/vir.0.055178-0
Loading

Data & Media loading...

Supplements

Supplementary material 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error